Log in

NASDAQ:DRAD - Digirad Stock Price, Forecast & News

$2.83
-0.05 (-1.74 %)
(As of 02/23/2020 06:16 AM ET)
Today's Range
$2.82
Now: $2.83
$2.93
50-Day Range
$2.56
MA: $3.00
$3.47
52-Week Range
$2.46
Now: $2.83
$11.40
Volume7,187 shs
Average Volume36,938 shs
Market Capitalization$5.80 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRAD
CUSIPN/A
Phone858-726-1600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$104.18 million
Cash Flow$3.14 per share
Book Value$12.75 per share

Profitability

Net Income$740,000.00

Miscellaneous

Employees452
Market Cap$5.80 million
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable

Receive DRAD News and Ratings via Email

Sign-up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter.


Digirad (NASDAQ:DRAD) Frequently Asked Questions

What is Digirad's stock symbol?

Digirad trades on the NASDAQ under the ticker symbol "DRAD."

When did Digirad's stock split? How did Digirad's stock split work?

Digirad shares reverse split on the morning of Wednesday, June 5th 2019. The 1-10 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 4th 2019. An investor that had 100 shares of Digirad stock prior to the reverse split would have 10 shares after the split.

How were Digirad's earnings last quarter?

Digirad Co. (NASDAQ:DRAD) issued its quarterly earnings results on Thursday, August, 2nd. The medical equipment provider reported $0.20 EPS for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.40. The medical equipment provider earned $27.08 million during the quarter. Digirad had a negative return on equity of 8.92% and a negative net margin of 5.74%. View Digirad's Earnings History.

When is Digirad's next earnings date?

Digirad is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Digirad.

Has Digirad been receiving favorable news coverage?

News coverage about DRAD stock has trended very negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Digirad earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Digirad.

Are investors shorting Digirad?

Digirad saw a increase in short interest in January. As of January 31st, there was short interest totalling 145,100 shares, an increase of 9.3% from the January 15th total of 132,700 shares. Based on an average daily volume of 34,000 shares, the days-to-cover ratio is presently 4.3 days. Currently, 7.8% of the shares of the company are sold short. View Digirad's Current Options Chain.

Who are some of Digirad's key competitors?

What other stocks do shareholders of Digirad own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Digirad investors own include AT&T (T), Cronos Group (CRON), Exelixis (EXEL), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Prospect Capital (PSEC), AbbVie (ABBV), Enterprise Products Partners (EPD) and NovaBay Pharmaceuticals (NBY).

Who are Digirad's key executives?

Digirad's management team includes the folowing people:
  • Mr. Matthew Gabel Molchan, Pres, CEO & Director (Age 52)
  • Mr. Martin B. Shirley, Pres of Digirad Imaging Solutions (Age 57)
  • Mr. David James Noble, COO & Interim CFO (Age 48)
  • Mr. Bob Halbert, Sr. Director of Human Resource

Who are Digirad's major shareholders?

Digirad's stock is owned by a number of of retail and institutional investors. Top institutional investors include Cannell Capital LLC (9.54%) and Ancora Advisors LLC (1.69%). Company insiders that own Digirad stock include Cannell Capital Llc, David J Noble, David James Noble, Jeffrey E Eberwein, Matthew G Molchan and Virgil Lott. View Institutional Ownership Trends for Digirad.

Which institutional investors are selling Digirad stock?

DRAD stock was sold by a variety of institutional investors in the last quarter, including Cannell Capital LLC and Ancora Advisors LLC. View Insider Buying and Selling for Digirad.

How do I buy shares of Digirad?

Shares of DRAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Digirad's stock price today?

One share of DRAD stock can currently be purchased for approximately $2.83.

How big of a company is Digirad?

Digirad has a market capitalization of $5.80 million and generates $104.18 million in revenue each year. Digirad employs 452 workers across the globe.View Additional Information About Digirad.

What is Digirad's official website?

The official website for Digirad is http://www.digirad.com/.

How can I contact Digirad?

Digirad's mailing address is 1048 INDUSTRIAL COURT, SUWANEE GA, 30024. The medical equipment provider can be reached via phone at 858-726-1600 or via email at [email protected]


MarketBeat Community Rating for Digirad (NASDAQ DRAD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Digirad and other stocks. Vote "Outperform" if you believe DRAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel